På baggrund af de oprindelige produktresuméer for cefuroximaxetil og anbefalingerne i litteraturen om anvendelse af cefuroxim til behandling af ukompliceret gonorré blev det hævdet, at medtagelsen af denne indikation er klinisk og farmakologisk velbegrundet.
Taking into account the originator SPCs of cefuroxime axetil and recommendations from the literature on the use of cefuroxime in the treatment of uncomplicated gonorrhoea, it was argued that the inclusion of this indication is fully justified from a clinical and pharmacological point of view.